AR085988A1 - Tratamientos de la infeccion del virus de la hepatitis c - Google Patents

Tratamientos de la infeccion del virus de la hepatitis c

Info

Publication number
AR085988A1
AR085988A1 ARP120101243A AR085988A1 AR 085988 A1 AR085988 A1 AR 085988A1 AR P120101243 A ARP120101243 A AR P120101243A AR 085988 A1 AR085988 A1 AR 085988A1
Authority
AR
Argentina
Prior art keywords
alisporivir
patient
treatment
hepatitis
during
Prior art date
Application number
Other languages
English (en)
Original Assignee
Novartis Ag
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45937376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Debiopharm Sa filed Critical Novartis Ag
Publication of AR085988A1 publication Critical patent/AR085988A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso de inhibidores de ciclofilina en el tratamiento de la infección del virus de la hepatitis C.Reivindicación 1: Alisporivir para el uso en el tratamiento de un paciente infectado con el virus de la hepatitis C, genotipo 1, en combinación con las normas asistenciales de tratamiento, caracterizado porque: (i) el paciente es un paciente de recaída o un paciente que no responde al tratamiento previo; y (ii) alisporivir se administra durante una fase inicial en una cantidad de alrededor de 600 mg, dos veces por día; seguido de la administración de alisporivir durante una segunda fase en una cantidad de alrededor de 600 a alrededor de 1000 mg, una vez por día. Reivindicación 8: El uso de alisporivir en la elaboración de un medicamento para el tratamiento de un paciente infectado con el virus de la hepatitis C, genotipo 1, caracterizado porque: (i) el paciente es un paciente de recaída o un paciente que no responde al tratamiento previo; y (ii) alisporivir se administra durante una fase inicial en una cantidad de alrededor de 600 mg, dos veces por día durante 7 días; seguido de la administración de alisporivir durante una segunda fase en una cantidad de alrededor de 600 a alrededor de 800 mg una vez por día, durante hasta 23, 47 ó 71 semanas; y donde alisporivir se administra en combinación con las normas asistenciales de tratamiento, durante toda la fase inicial y la segunda fase. Reivindicación 11: Una composición farmacéutica que comprende alisporivir para el uso de acuerdo con la reivindicación 1.
ARP120101243 2011-04-13 2012-04-11 Tratamientos de la infeccion del virus de la hepatitis c AR085988A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161474946P 2011-04-13 2011-04-13

Publications (1)

Publication Number Publication Date
AR085988A1 true AR085988A1 (es) 2013-11-13

Family

ID=45937376

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101243 AR085988A1 (es) 2011-04-13 2012-04-11 Tratamientos de la infeccion del virus de la hepatitis c

Country Status (18)

Country Link
US (2) US20150104415A1 (es)
EP (1) EP2696883A1 (es)
JP (1) JP2014510772A (es)
KR (1) KR20140011379A (es)
CN (1) CN103648516A (es)
AR (1) AR085988A1 (es)
AU (2) AU2012241859A1 (es)
BR (1) BR112013025934A2 (es)
CA (1) CA2832829A1 (es)
CL (1) CL2013002914A1 (es)
IL (1) IL228725A0 (es)
MA (1) MA35029B1 (es)
MX (1) MX2013011941A (es)
RU (1) RU2013150344A (es)
SG (2) SG10201602184TA (es)
TN (1) TN2013000397A1 (es)
TW (1) TW201247217A (es)
WO (1) WO2012140082A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2006038088A1 (en) 2004-10-01 2006-04-13 Debiopharm Sa Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物
WO2008052722A2 (en) 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug

Also Published As

Publication number Publication date
SG10201602184TA (en) 2016-04-28
RU2013150344A (ru) 2015-05-20
TW201247217A (en) 2012-12-01
BR112013025934A2 (pt) 2016-09-06
JP2014510772A (ja) 2014-05-01
US20160235808A1 (en) 2016-08-18
US20150104415A1 (en) 2015-04-16
CA2832829A1 (en) 2012-10-18
MX2013011941A (es) 2014-05-28
KR20140011379A (ko) 2014-01-28
NZ615539A (en) 2016-01-29
EP2696883A1 (en) 2014-02-19
AU2016200061A1 (en) 2016-01-28
TN2013000397A1 (en) 2015-01-20
CL2013002914A1 (es) 2014-06-27
MA35029B1 (fr) 2014-04-03
IL228725A0 (en) 2013-12-31
AU2012241859A1 (en) 2013-10-10
WO2012140082A1 (en) 2012-10-18
CN103648516A (zh) 2014-03-19
SG193908A1 (en) 2013-11-29

Similar Documents

Publication Publication Date Title
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201170669A1 (ru) Лечение пирфенидоном пациентов с атипичной функцией печени
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
NZ595767A (en) Composition for the treatment of prostate cancer
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
AR083337A1 (es) Tratamientos de infeccion por el virus de hepatitis c
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
MX2009006311A (es) Terapia de combinacion para tratar infecciones de hepatitis c.

Legal Events

Date Code Title Description
FB Suspension of granting procedure